Tissue‐resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression

Macrophage is an essential part of the tumor immune microenvironment of pancreatic ductal adenocarcinoma. In our study, we explored the CXCR4+ macrophages subset on its prognosis value, immune profile and distinct function in pancreatic cancer progression. Specimens from 102 postoperative pancreatic patients were analyzed by flow cytometry or immune‐fluorescence, and the prognostic value of CXCR4+ macrophages infiltration was further determined by Cox regression. In silico analysis on TCGA, ICGC database and single‐cell sequencing of pancreatic ductal adenocarcinoma further validated our findings. We found that high CXCR4+ macrophages infiltration was associated with poor overall survival (P < .01) and disease‐free survival (P < .05) as an independent factor. CXCR4+ macrophages exhibited an M2 protumor phenotype with high expression of CD206. The function of CXCR4+ macrophages was further analyzed in the murine orthotopic PDAC model with its tumor promotion effect and inhibition of CD8+ T cells. Mechanistic and RNA‐seq analysis showed that CXCR4+ macrophages participated in extracellular matrix remodeling procedures and especially secreted SPARC through CXCR4/PI3K/Akt pathway promoting tumor proliferation and migration. Our study reveals that CXCR4+ macrophages infiltration is an indicator of poor prognosis of PDAC and targeting these cells was potentially crucial in immunotherapy of PDAC.

[1]  Zhenyu Liao,et al.  Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer , 2022, EBioMedicine.

[2]  Zhenyu Liao,et al.  Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21 , 2021, Cancers.

[3]  C. Rao,et al.  Naproxen inhibits spontaneous lung adenocarcinoma formation in KrasG12V mice , 2021, Neoplasia.

[4]  Shanshan Li,et al.  Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression , 2021, Hepatology.

[5]  Jianguo Wang,et al.  Targeting tumor-associated macrophages to synergize tumor immunotherapy , 2021, Signal Transduction and Targeted Therapy.

[6]  Wen-quan Wang,et al.  Human splenic TER cells: A relevant prognostic factor acting via the artemin‐GFRα3‐ERK pathway in pancreatic ductal adenocarcinoma , 2020, International journal of cancer.

[7]  Jessica S. Yu,et al.  Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer , 2020, Nature Cancer.

[8]  G. Miller,et al.  Regulation and modulation of antitumor immunity in pancreatic cancer , 2020, Nature Immunology.

[9]  Stephen M. Shaw,et al.  BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial , 2020, Nature Medicine.

[10]  A. Maitra,et al.  Pancreatic cancer stroma: an update on therapeutic targeting strategies , 2020, Nature Reviews Gastroenterology & Hepatology.

[11]  L. Jones,et al.  Fibronectin acts as a molecular switch to determine SPARC function in pancreatic cancer. , 2020, Cancer letters.

[12]  M. Bajénoff,et al.  Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer , 2020, The Journal of experimental medicine.

[13]  Le Xu,et al.  Tumor-infiltrating TNFRSF9+ CD8+ T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response , 2020, Oncoimmunology.

[14]  M. Vignali,et al.  Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer , 2019, Clinical Cancer Research.

[15]  Alexander H. E. Morrison,et al.  Immunotherapy and Prevention of Pancreatic Cancer. , 2018, Trends in cancer.

[16]  M. Hollingsworth,et al.  Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy☆ , 2017, Pharmacology & therapeutics.

[17]  Jingqin Luo,et al.  Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. , 2017, Immunity.

[18]  Z. Halpern,et al.  Tumor macrophages are pivotal constructors of tumor collagenous matrix , 2016, The Journal of experimental medicine.

[19]  Hong Zhao,et al.  CXCR4 in breast cancer: oncogenic role and therapeutic targeting , 2015, Drug design, development and therapy.

[20]  W. Knoefel,et al.  CXCR4-A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis , 2015, PloS one.

[21]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[22]  J. Pollard,et al.  A Lineage of Myeloid Cells Independent of Myb and Hematopoietic Stem Cells , 2012, Science.

[23]  Beverly A. Teicher,et al.  CXCL12 (SDF-1)/CXCR4 Pathway in Cancer , 2010, Clinical Cancer Research.

[24]  M. Colombo,et al.  Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. , 2008, Cancer research.